Erythropoietin Drug Market
Global Erythropoietin Drug Market Size, Share & Trends Analysis Report by Product type (Epoetin Alfa, Epoetin Beta, Darbepoetin-Alfa, and Others), By Application (Hematology, Kidney Disorders, Cancer, and Others) Forecast 2022-2028
The global Erythropoietin Drug market is anticipated to be at a considerable CAGR of 5.6%. The factor which can be seen as a driving pull to the growing demand for the erythropoietin drug market is growing anaemic conditions caused by end-stage renal disease. Erythropoietin is a hormone that is responsible for the production of red blood cells in the bone marrow. The rise in cases of anemia in all regions of the world is posing a growth in the market of the erythropoietin drug market. One major reason for anemia is a consistent rise in chronic kidney diseases. As per WHO, 42% of children who are less than 5 years of age and around 40% of pregnant women worldwide are suffering from anemia in 2021. This drug is used for the treatment of chemotherapy-induced anemia. For instance, in Aug 2021, a study published in CJASN, clinical trials have indicated that an oral drug Roxadustat has proved effective in the treatment of anemia caused by chronic kidney disease.
Impact of COVID-19 Pandemic on Global Erythropoietin Drug Market
Covid-19 Pandemic has affected every sector of the world in some way. Global Erythropoietin Drug Market saw a drop as, during covid-19, hospital facilities, global drug supply was on a pause for some time. At this time market for this drug was affected for some time. Drugs like Erythropoietin are given under medical supervision.
Segmental Outlook
The global erythropoietin drug market is segmented based on Product type and application. Based on product type, the market is segmented into epoetin alfa, epoetin beta, darbepoetin-alfa, and others. Based on the application, the market is sub-segmented into hematology, kidney disorders, cancer, and others.
Global Erythropoietin Drug Market Share by Product Type, 2021 (%)
Epoetin Alfa is Anticipated to Hold a Prominent Share in the Global Erythropoietin Drug Market
Epoetin alfa is anticipated to hold a prominent market share in the global Erythropoietin Drug market during the forecast period. Epoetin alfa is used for the treatment of non-regenerative anemia. This drug is used to treat myelosuppression which is mainly caused by chemotherapy. It has been found effective in chronic anemia. This drug is preferred by medical health care experts in all regions of the world. It was the first drug to be approved by US FDA for treating anemia resulting from various health problems. For instance, in Feb 2022, Fanconi anemia is a rare disease for which there is no treatment defined. Recent advancements in medical science have made treatment possible with hematopoietic stem-cell transplantation. In this procedure, HSC cells are replaced with donor cells which are obtained from the blood, marrow, or umbilical cord of the donor.
Regional Outlooks
The global erythropoietin drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). North America is anticipated to lead the erythropoietin drug market during the forecast period. Growth factors are rising cases of cancer, chronic kidney disease, and the rising case of HIV which are significantly driving the drug.
Global Erythropoietin Drug Market Growth, by Region 2022-2028
North America is Estimated to Hold the Major Share in the Global Erythropoietin Drug Market
Geographically, it is anticipated that the major share of the market will be taken by North America and this region will lead during the forecast period. A major factor for the regional growth is attributed to the increasing cases of HIV. There is multifactorial pathogenesis of HIV in anemia. Anemia is caused in HIV patients due to the destruction of red blood cells, suppression of red blood cell production, deficiency of erythropoietin in the body. As per the Cleveland clinic journal of medicine, around 90% of people with advanced HIV have anemia in some form. For instance, in Feb 2022, Gilead Sciences Inc. announced to present their data on the company’s HIV development programs in the CROI 2022. Data will reflect the company’s enduring research and new findings in the field of HIV infections. The company has been working in the field to cater needs of people suffering from HIV and aiming to eradicate HIV.
Market Players Outlook
The major companies serving the global Erythropoietin Drug market include Amgen Inc., Johnson & Johnson, Hospira Inc., F.Hoffman-La Roche AG, LG Chem, and others. The market players are working in a consistent way to provide their consumers with medicines that are effective for Erythropoietin deficiency. And for this, they are adopting different market strategies such as mergers and acquisitions, new product launches, business expansion, partnership collaboration, and others. For instance, in Feb 2022, the European Commission has approved the Oxbryta drug. This drug will be used for the treatment of hemolytic anemia. This medicine can be taken once daily, in oral form. This is the first medicine in Europe which is sickle hemoglobin polymerization inhibitor. This drug increases hemoglobin levels in the body.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Erythropoietin Drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Erythropoietin Drug Market
• Recovery Scenario of Global Erythropoietin Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Amgen Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Johnson and Johnson
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Hospira Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. F.Hoffman-La Roche AG
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. LG Chem.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Erythropoietin Drug Market by Product type
4.1.1. Epoetin Alfa
4.1.2. Epoetin Beta
4.1.3. Darbepoetin Alfa
4.1.4. Others
4.2. Global Erythropoietin Drug Market by Application
4.2.1. Hematology
4.2.2. Kidney Disorders
4.2.3. Cancer
4.2.4. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Biocon Ltd.
6.2. Celltrion Inc.
6.3. Dr. Reddy’s Laboratories Ltd.
6.4. Emcure Pharmaceuticals
6.5. Intas Pharmaceuticals
6.6. Kirin Holdings Co.Ltd.
6.7. Novartis International AG
6.8. Pfizer Inc.
6.9. Ranbaxy Laboratories Ltd.
6.10. Sun Pharmaceuticals Industries Ltd.
6.11. Teva Pharmaceutical Industries Ltd.
1. GLOBAL ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
2. GLOBAL EPOETIN ALFA ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL EPOETIN BETA ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL DARBEPOIETIN ALFA ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHERS ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
7. GLOBAL ERYTHROPOIETIN DRUG IN HEMATOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL ERYTHROPOIETIN DRUG IN KIDNEY DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL ERYTHROPOIETIN DRUG IN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
13. NORTH AMERICAN ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
14. EUROPEAN ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. EUROPEAN ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
16. EUROPEAN ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS PRODUCT TYPE, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
20. REST OF THE WORLD ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. REST OF THE WORLD ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2021-2028 ($ MILLION)
22. REST OF THE WORLD ERYTHROPOIETIN DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL ERYTHROPOIETIN DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL ERYTHROPOIETIN DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL ERYTHROPOIETIN DRUG MARKET, 2021-2027 (%)
4. GLOBAL ERYTHROPOIETIN DRUG MARKET SHARE BY PRODUCT, 2021 VS 2028 (%)
5. GLOBAL EPOETIN ALFA ERYTHROPOIETIN DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL EPOETIN BETA ERYTHROPOIETIN DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL DARBEPOETIN ALFA ERYTHROPOIETIN DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL ERYTHROPOIETIN DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
9. GLOBAL ERYTHROPOIETIN DRUG IN HEMATOLOGY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL ERYTHROPOIETIN DRUG IN KIDNEY DISORDER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL ERYTHROPOIETIN DRUG IN CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL ERYTHROPOIETIN DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. US ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
14. CANADA ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
15. UK ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. FRANCE ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. GERMANY ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. ITALY ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. SPAIN ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. REST OF EUROPE ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. INDIA ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. CHINA ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. JAPAN ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. SOUTH KOREA ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF ASIA-PACIFIC ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF THE WORLD ERYTHROPOIETIN DRUG MARKET SIZE, 2021-2028 ($ MILLION)
